Core Insights - Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete, with topline data expected in Q3 2026 [1] - Enrollment in the psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of SKYWAY is on track, with topline readouts anticipated in Q4 2026 [1] - The SKYLINE platform trial in ulcerative colitis (UC) is enrolling ahead of schedule, with Part A readouts starting in Q2 2026 [1] Company Overview - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases [5] - The company's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23 [5] Product Insights - SPY072 is an investigational antibody targeting TL1A, designed for superior potency and convenience, potentially allowing for quarterly or biannual subcutaneous maintenance dosing [4] - The SKYWAY Phase 2 trial is a randomized and placebo-controlled study evaluating SPY072 in patients with moderately to severely active RA, PsA, or axSpA [3]

Core Insights - Spyre Therapeutics is on track to deliver six proof-of-concept readouts in 2026 from its SKYLINE and SKYWAY Phase 2 trials, with initial results from the SKYLINE trial in ulcerative colitis expected in Q2 2026 and results from the SKYWAY trial in rheumatic diseases anticipated in Q4 2026 [1][4][5] Financial Overview - As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $757 million, providing a financial runway into the second half of 2028 [1][13] - The company raised $316.2 million in gross proceeds from a public offering of common stock in October 2025 [13] - Research and Development (R&D) expenses for Q4 2025 were $44.6 million, a decrease from $50.5 million in Q4 2024, primarily due to lower early-stage R&D activities [14] - General and Administrative (G&A) expenses increased to $12.5 million in Q4 2025 from $10.8 million in Q4 2024, driven by higher headcount [14] Development Pipeline - The company is developing long-acting antibodies targeting α4β7, TL1A, and IL-23 to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases [3][17] - The SKYLINE Phase 2 trial includes an open-label assessment of safety and preliminary efficacy for investigational monotherapies in patients with moderately to severely active ulcerative colitis, with data readouts expected to begin in 2026 [4][10] - The SKYWAY Phase 2 trial is evaluating the anti-TL1A antibody in three rheumatic diseases, with proof-of-concept data expected in Q4 2026 [5][10] Clinical Trials - The investigational therapies in the SKYLINE and SKYWAY trials include SPY001, SPY002, SPY072, and SPY003, all designed for infrequent subcutaneous maintenance dosing [6][7][8] - SPY001 targets α4β7, while SPY002 and SPY072 are anti-TL1A antibodies, and SPY003 targets the p19 subunit of IL-23 [6][7][8] - The company plans to investigate rational combinations of its proprietary antibodies in clinical trials to enhance efficacy in IBD [9][19] Market Context - IBD affects approximately 2.4 million individuals in the U.S., while rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis collectively impact over three million individuals [3]

Core Insights - Spyre Therapeutics reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, indicating a well-tolerated profile and an approximately 85-day half-life, supporting quarterly or biannual maintenance dosing [1] - The company initiated the Phase 2 SKYWAY basket study for SPY072, focusing on TL1A inhibition in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis [1] - Spyre is on track for six proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials [1] - The company strengthened its balance sheet with $316 million in gross proceeds from a public offering, resulting in $783 million in pro forma cash as of September 30, 2025, with a projected runway into the second half of 2028 [1][13] Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on long-acting antibodies and antibody combinations aimed at redefining the standard of care for inflammatory bowel disease and rheumatic diseases [1][16] - The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, with a market potential exceeding $60 billion in annual revenue across its indications [2][3] Development Pipeline - The company is advancing multiple investigational antibodies, including SPY001, SPY002, SPY003, and SPY072, targeting validated mechanisms for the treatment of inflammatory bowel disease and rheumatic diseases [4][10][11] - SPY001 targets α4β7 and is designed for infrequent subcutaneous maintenance dosing, while SPY002 and SPY072 are anti-TL1A monoclonal antibodies also engineered for extended half-lives [5][6][7] - The SKYLINE Phase 2 platform trial includes SPY001, SPY002, and SPY003, with Part A focusing on safety and preliminary efficacy, and Part B planned for randomized assessments [10] Financial Performance - As of September 30, 2025, Spyre reported cash, cash equivalents, and marketable securities totaling $486.2 million, with pro forma cash reflecting $782.7 million after a recent public offering [13] - Research and development expenses for Q3 2025 were $45.2 million, slightly higher than $44.7 million in Q3 2024, driven by increased clinical trial costs [14] - The net loss for Q3 2025 was $11.2 million, a significant improvement from a net loss of $69.0 million in Q3 2024 [15][27]

Core Insights - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases, recently presenting scientific data at the ACR Convergence Congress [1][3] Group 1: Product Development - The company shared follow-up data from a Phase 1 study of SPY072, an anti-TL1A agent, indicating it is well tolerated and supports quarterly or biannual dosing [2] - New preclinical data showed that anti-TL1A antibody treatment is as effective or more effective than etanercept in a rodent model of collagen-induced arthritis, supporting ongoing Phase 2 studies for various rheumatic diseases [2] Group 2: Pipeline and Research - Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, aiming to redefine treatment standards for IBD and rheumatic diseases [3]

Core Insights - SPY072 is a potential first- and best-in-class anti-TL1A antibody designed for the treatment of rheumatic diseases, with a dosing regimen of quarterly or twice-yearly subcutaneous injections [1][2][5] - The SKYWAY study is currently evaluating SPY072 in patients with moderate-to-severely active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), with proof-of-concept data expected in 2026 [1][3] - The company anticipates delivering nine proof-of-concept readouts from the SKYWAY and SKYLINE trials between 2026 and 2027, targeting a market with over $60 billion in annual revenue [4] Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations [6] - The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, aiming to address significant unmet medical needs in rheumatic diseases [6] Clinical Development - The SKYWAY Phase 2 trial is a randomized, placebo-controlled study assessing SPY072 in patients with inadequate response to existing therapies, with topline data expected in 2026 [3][5] - Interim data from a Phase 1 trial indicated that SPY072 was well tolerated and demonstrated prolonged pharmacokinetics, suggesting its potential efficacy in treating rheumatic diseases [5]

Core Insights - Spyre Therapeutics reported positive interim Phase 1 results for two next-generation TL1A antibodies, indicating they were well-tolerated and supported quarterly or biannual dosing with full TL1A engagement for up to 20 weeks [1][2] - The company initiated the Phase 2 SKYLINE-UC platform study to evaluate three optimized monotherapies and three potentially paradigm-changing combinations for ulcerative colitis [1][3] - Spyre is on track to begin the Phase 2 SKYWAY-RD basket study for TL1A inhibition in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis in Q3 2025 [1][10] - The company has a strong cash position of $526.6 million as of June 30, 2025, with an expected runway into the second half of 2028 [1][11] Development Pipeline Overview - Spyre's approach combines advanced antibody engineering, dose optimization, and rational therapeutic combinations to enhance efficacy and convenience in treating inflammatory bowel disease (IBD) and other immune-mediated diseases [3][15] - IBD affects approximately 2.4 million individuals in the U.S., while rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) affect over 1.5 million and nearly 3 million individuals, respectively [3][4] Financial Performance - Research and Development (R&D) expenses for Q2 2025 totaled $40.1 million, up from $32.6 million in Q2 2024, primarily due to increased clinical trial expenses [12] - General and Administrative (G&A) expenses were $11.8 million for Q2 2025, slightly higher than $11.5 million in Q2 2024 [12] - The net loss for Q2 2025 was $36.7 million, compared to a net loss of $38.8 million in Q2 2024, including non-cash stock-based compensation expenses [14][24]

Clinical Trial Updates - SPY002 and SPY072 met Phase 1 objectives, and the company plans to advance both into Phase 2[18] - The company is launching SKYLINE-UC, a Phase 2 platform study in ulcerative colitis evaluating three monotherapies and three combinations[11, 58] - The company is unveiling SKYWAY-RD, a Phase 2 basket study evaluating anti-TL1A in three rheumatologic conditions[11, 75] - The company anticipates 9 proof-of-concept readouts in 2026-27 for the treatment of IBD and beyond[25, 103] SPY002 and SPY072 Phase 1 Results - In a Single Ascending Dose (SAD) study, 11 out of 40 (28%) subjects in the SPY002 group experienced at least one Treatment Emergent Adverse Event (TEAE)[36] - In a Single Ascending Dose (SAD) study, 14 out of 40 (35%) subjects in the SPY072 group experienced at least one Treatment Emergent Adverse Event (TEAE)[38] - SPY002 demonstrated an approximate 75-day half-life[40, 42] - SPY002 and SPY072 suppressed free TL1A through 20-weeks of follow-up at the lowest dose tested[43] Trial Design and Cost Efficiency - The Phase 2 platform trial in UC is expected to achieve 40% cost savings compared to individual Phase 2 studies[24] - The Phase 2 basket trial in rheumatological diseases is expected to achieve 35% cost savings compared to individual Phase 2 studies[24] Financial Runway - The company has $565 million cash with runway into the second half of 2028[103]